HC Wainwright Brokers Reduce Earnings Estimates for MIRM

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Research analysts at HC Wainwright reduced their Q1 2026 EPS estimates for Mirum Pharmaceuticals in a report issued on Thursday, February 26th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.18) per share for the quarter, down from their prior estimate of $0.02. HC Wainwright currently has a “Buy” rating and a $130.00 target price on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.43) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at $0.06 EPS, FY2026 earnings at ($0.41) EPS, FY2027 earnings at $0.63 EPS, FY2028 earnings at $2.47 EPS, FY2029 earnings at $4.59 EPS and FY2030 earnings at $7.07 EPS.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.13). The company had revenue of $148.93 million for the quarter, compared to the consensus estimate of $141.78 million. Mirum Pharmaceuticals had a negative net margin of 4.48% and a negative return on equity of 8.53%. The company’s revenue for the quarter was up 49.8% compared to the same quarter last year. During the same period last year, the firm posted $1.00 earnings per share.

Other equities research analysts have also issued reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a report on Thursday, January 22nd. Royal Bank Of Canada lowered their target price on Mirum Pharmaceuticals from $130.00 to $128.00 and set an “outperform” rating for the company in a report on Thursday. Citizens Jmp dropped their price objective on shares of Mirum Pharmaceuticals from $140.00 to $132.00 and set a “market outperform” rating on the stock in a report on Thursday. Robert W. Baird increased their target price on Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. Finally, TD Cowen lifted their price target on Mirum Pharmaceuticals from $115.00 to $117.00 and gave the company a “buy” rating in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $114.92.

Mirum Pharmaceuticals Trading Up 0.1%

Shares of MIRM stock opened at $92.29 on Monday. The firm has a market capitalization of $5.57 billion, a P/E ratio of -192.27 and a beta of 0.52. The company has a quick ratio of 2.55, a current ratio of 2.67 and a debt-to-equity ratio of 0.98. The stock’s fifty day simple moving average is $93.40 and its 200 day simple moving average is $79.28. Mirum Pharmaceuticals has a twelve month low of $36.88 and a twelve month high of $109.28.

Insider Transactions at Mirum Pharmaceuticals

In other news, SVP Jolanda Howe sold 968 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $103.30, for a total transaction of $99,994.40. Following the transaction, the senior vice president owned 4,503 shares of the company’s stock, valued at $465,159.90. This represents a 17.69% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Patrick J. Heron acquired 131,425 shares of the company’s stock in a transaction on Friday, January 23rd. The shares were acquired at an average cost of $68.48 per share, for a total transaction of $8,999,984.00. Following the completion of the acquisition, the director owned 459,010 shares of the company’s stock, valued at approximately $31,433,004.80. The trade was a 40.12% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders sold 45,136 shares of company stock valued at $4,352,029. 22.87% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Cullen Frost Bankers Inc. bought a new position in Mirum Pharmaceuticals in the fourth quarter valued at $30,000. MCF Advisors LLC lifted its position in Mirum Pharmaceuticals by 76.4% in the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after purchasing an additional 185 shares during the last quarter. Eurizon Capital SGR S.p.A. purchased a new stake in Mirum Pharmaceuticals during the 4th quarter valued at $32,000. CIBC Private Wealth Group LLC purchased a new stake in shares of Mirum Pharmaceuticals during the fourth quarter worth about $32,000. Finally, Quantbot Technologies LP bought a new stake in shares of Mirum Pharmaceuticals in the 3rd quarter worth approximately $33,000.

Mirum Pharmaceuticals News Roundup

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Q4 revenue beat and strong product growth — Mirum reported ~50% year-over-year revenue growth driven by Livmarli and other drug sales, topping estimates and providing fundamental support for the stock. Mirum’s Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues
• Positive Sentiment: Analyst upgrades/target raises — Stifel raised its price target to $125 (buy) and TD Cowen raised its target to $117 (buy), signaling continued analyst confidence and suggesting meaningful upside from current levels. Analyst Coverage (Benzinga)
• Neutral Sentiment: Analyst consensus roundup — several coverage notes were published (13-analyst roundup) that summarize mixed but generally constructive views; useful for gauging street positioning. 13 Analysts Have This To Say About Mirum Pharmaceuticals
• Neutral Sentiment: Other analyst moves — RBC and Citizens JPM trimmed targets modestly but kept outperform/market outperform ratings, indicating conviction despite small PT adjustments. RBC Commentary (Street Insider)
• Neutral Sentiment: Earnings call and transcripts available — management commentary from the Q4 call provides more detail on commercialization cadence and upcoming catalysts; worth reviewing for guidance tone and commercialization cadence. Q4 2025 Earnings Call Transcript (Fool)
• Negative Sentiment: EPS miss — Mirum reported a GAAP loss of ($0.11) vs. consensus of $0.02, a notable EPS miss that can weigh on sentiment despite the revenue beat. Mirum Reports Q4 Loss, Tops Revenue Estimates (Zacks)
• Negative Sentiment: Guidance mixed — management set FY2026 revenue guidance of $630–$650M vs. a consensus near $646M, leaving limited upside to Street expectations and creating potential downside if execution slips. Press Release / Guidance (Company PDF)
• Negative Sentiment: Short-term pullback coverage — commentary and retail pieces explaining intra-day/short-term weakness (e.g., articles on why MIRM was down) may amplify volatility even as fundamentals improve. Why MIRM Stock Is Down 13.46% (AAII)

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.